NRES Committee London - South East
Bristol Research Ethics Committee Centre
Level 3, Block B
Whitefriars,
Lewins Mead,
Bristol
BS1 2NT

Telephone: 0117 342 1382
Facsimile: 0117 342 0445

01 March 2013

Professor Philip M. W. Bath
Professor of Stroke Medicine
University of Nottingham
Division of Stroke Medicine - Research Dept
Clinical Sciences Building
City Hospital Campus
Hucknall Road
Nottingham
NG5 1PB

Dear Professor Bath

Study Title:	**Safety and tolerability of clopidogrel when added to aspirin and dipyridamole in high risk patients with recent ischaemic stroke: a randomised controlled trial**
REC reference:	**08/H1102/112**
Protocol number:	**31350**
EudraCT number:	**2007-006749-42**
Amendment number:	**13**
Amendment date:	**21 December 2012**
IRAS project ID:	

Thank you for submitting the above amendment, which was received on 22 January 2013.

Research Site	Principal Investigator / Local Collaborator
County Durham & Darlington NHS Foundation	Bernard Esisi
Buckinghamshire Healthcare Trust	Matthew Burn
Heart of England NHS Foundation Trust	Ibrahim Memon
South Tees Hospitals	David Broughton
Wirral University	Ruth Davies
Peterboroush and Stamford Hospitals	Peter Owusu-Ahyei
Epsom & St Helier University	Janet Putterill
University College Halton	Richard Perry
Warrington and Halton	Karim Mahawish
North Tees and Hartlepool	David Bruce
South London Healthcare NHS Trust	Bartlomiej Piechowski-Jozwiak
The Royall Free Hampstead	Charlie Davie

Norfolk and Norwich University	Kneale Metcalfe
The Queen Elizabeth Hospital Kimngs Lynn NHS Trust Grayton	Raj Shekhar
Plymouth Hospitals NHS Trust Derriford Road	Azlisham Mohd Nor
Hampshire Hospitals NHS Foundation Trust Basingstoke and North Hampshire Hospital	Elio Giallombardo
Weston Area Health NHS Trust Weston General Hospital	Harbans Bhakri
West Suffolk Hospital NHS Trust	Abul Azim

The amendment relates solely to the addition of new site(s) and/or investigator(s) within the National Health Service (NHS) or Health and Social Care (HSC) in Northern Ireland. The site-specific assessment for the site(s) will therefore form part of the research governance review. The Site-Specific Information (SSI) Form for the site should be included with the application for R&D approval.

On behalf of the Committee, I am pleased to confirm the extension of the favourable opinion to the new site(s) and/or investigator(s), subject to management permission being given by the relevant NHS/HSC R&D office(s) prior to the study starting at the site.

Statement of compliance

This Committee is recognised by the United Kingdom Ethics Committee Authority under the Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of clinical trials of investigational medicinal products.

The Committee is fully compliant with the Regulations as they relate to ethics committees and the conditions and principles of good clinical practice.

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

08/H1102/112	**Please quote this number on all correspondence**

Yours sincerely

T. Fairman

Mr Tom Fairman
Assistant Committee Co-ordinator

Email: nrescommittee.london-southeast@nhs.net

Copy to: *Mr Paul Cartledge*